Medical management of severe head injury: present and future

The comparative efficacy of various treatment algorithms in improving outcome from severe head injury (SHI) has never been tested in a prospective, randomized, controlled trial. Indeed, there are few hard data on the influence on outcome of most of the individual treatment modalities used alone. The medical management algorithm presented here is an exercise in evaluating the strength of what studies do exist and attempting to balance the relative risk/benefit ratios of the various treatment modalities. This algorithm, based on the information contained in this issue of New Horizons, divides the patient's course into two segments based on the insertion of an intracranial pressure (ICP) monitor. Before the establishment of ICP monitoring, based on the devastating effects of secondary insults on the injured brain, the main emphasis should be on full resuscitation of the patient. Any "prophylactic" treatment of the intracranial injury that has the potential of interfering with full resuscitation (e.g., mannitol) or inducing secondary ischemic insults (e.g., hyperventilation) should be reserved for the specific instance of evidence of herniation or neurologic deterioration; if such deterioration should occur, however, it should be promptly treated. Following computed tomography imaging and any necessary surgical procedures, and ICP monitor should be inserted and treatment directed specifically toward controlling ICP and maintaining a cerebral perfusion pressure > or = 70 mm Hg. An algorithm for treating intracranial hypertension is presented, based on the successive application of effective agents with increasing attendant risks. Outside of the burgeoning pharmacologic approaches to the injured brain, the future of the management of SHI involves: a) subjecting the various protocols and treatment modalities presently in use to prospective, randomized, controlled trials in order to formally establish their utility; b) developing organized, regionalized trauma care systems which facilitate the universal delivery of the level of care necessary to effectively apply today's head injury management protocols; and c) furthering our development of targeted therapy in treating SHI. Targeted therapy involves recognizing and understanding the various pathophysiologic processes that occur in the injured brain over the acute course of treatment and the responses of these processes to various treatment modalities. Such processes include vasogenic and cytotoxic edema, increased cerebral blood volume, altered cerebrovascular autoregulation, vasospasm, etc.(ABSTRACT TRUNCATED AT 400 WORDS)